Observational studies suggest that male circumcision may provide protection against HIV-1 infection. A randomized, controlled, intervention trial was conducted in a general population of South Africa to test this hypothesis.
This study is a randomized controlled intervention trial. This multi-centre study will take place in 3 centers located around Johannesburg, in the areas of Orange Farm, Sebokeng and Evaton. The intervention group patients (circumcised at the beginning of the trial) and the control group (uncircumcised men) will be followed during 21 months (from M.0 to M. 21). Randomization and medicalized circumcision will be performed at M.0 in the intervention group and might be optional in the control group at end of study. The medicalized circumcision effectiveness will be evaluated on and after M.3 (3 months after medicalized circumcision). Incidences (of HIV, HSV-2 infections and genital ulcer disease) will be compared from M.3 to M.21 between the intervention group and the control group. An intermediate analysis will take place at M. 12.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
3,274
MC Centre
Orange Farm, Johannesburg, South Africa
Measure the protective effect of medicalized male circumcision on HIV infection
Time frame: M3, M12 and M21
Measure the protective effect on infections by the genital herpes agent Herpes simplex virus type 2 (HSV-2)
Time frame: M3, M12 and M21
Measure the protective effect on the incidence of genital ulcer disease
Time frame: M3, M12 and M21
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.